BMS’s Opdivo On Track For Esophageal Cancer Indication

Opdivo showed a 23% fall in the risk of death and 2.5-month improvement in median overall survival compared to chemotherapy in Phase III esophageal cancer trial.

Esophageal cancer
Opdivo Extended Overall Survival In ATTRACTION-3 Trial Versus Chemo • Source: Shutterstock

Results from Bristol-Myers Squibb Co.. and Ono Pharmaceutical Co. Ltd.’s Phase III ATTRACTION-3 trial showed Opdivo (nivolumab) ‘significantly’ extended overall survival (OS) compared with chemotherapy in patients with previously treated advanced esophageal squamous cell carcinoma, enhancing the PD-1 inhibitor’s likelihood of approval in that indication.

The trial data, presented at the European Society for Medical Oncology (ESMO) 2019 Annual Congress in Barcelona, Spain, showed Opdivo...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Immuno-oncology

More from Anticancer